Full-length dysferlin expression driven by engineered human dystrophic blood derived CD133+ stem cells.
Mirella Meregalli1, Claire Navarro, Clementina Sitzia
1Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Centro Dino Ferrari, Milano, Italy.
The FEBS Journal
|September 14, 2013
Summary
Gene therapy using lentiviral vectors successfully restored dysferlin protein in stem cells from Miyoshi myopathy patients. This approach corrected muscle membrane repair deficits in mice, offering a potential new treatment for dysferlinopathies.
Area of Science:
- Biomedical Science
- Regenerative Medicine
- Molecular Biology
Background:
- Dysferlin protein is crucial for skeletal and cardiac muscle membrane repair.
- Mutations in the dysferlin gene cause Miyoshi myopathy and limb-girdle muscular dystrophy type 2B.
- Current therapeutic strategies for dysferlinopathies face significant challenges.
Purpose of the Study:
- To investigate the potential of lentivirus-mediated gene therapy for dysferlinopathies.
- To assess the efficacy of engineered stem cells in restoring dysferlin function.
- To evaluate a novel therapeutic approach for Miyoshi myopathy.
Main Methods:
- Isolated blood-derived CD133+ stem cells from Miyoshi myopathy patients.
- Engineered stem cells using a lentiviral vector to express full-length dysferlin.
- Transplanted engineered stem cells into dysferlin-null mice (scid/blAJ).
Main Results:
- Engineered stem cells showed sufficient dysferlin expression after transplantation.
- Corrected functional deficits in skeletal muscle membrane repair in treated mice.
- Previous attempts with antisense oligonucleotides showed limited success.
Conclusions:
- Lentivirus-mediated delivery of full-length dysferlin in patient-derived stem cells is a viable therapeutic strategy.
- This approach offers a promising alternative for treating dysferlinopathies.
- The study provides the first evidence for this gene therapy approach in Miyoshi myopathy models.
